270 related articles for article (PubMed ID: 36577426)
1. Clinical practice guidelines and real-life practice on hepatocellular carcinoma: the Hong Kong perspective.
Hui RW; Mak LY; Cheung TT; Lee VH; Seto WK; Yuen MF
Clin Mol Hepatol; 2023 Apr; 29(2):217-229. PubMed ID: 36577426
[TBL] [Abstract][Full Text] [Related]
2. Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective.
Su TH; Wu CH; Liu TH; Ho CM; Liu CJ
Clin Mol Hepatol; 2023 Apr; 29(2):230-241. PubMed ID: 36710607
[TBL] [Abstract][Full Text] [Related]
3. Distribution of tumor stage and initial treatment modality in patients with primary hepatocellular carcinoma.
Xiang X; Zhong JH; Wang YY; You XM; Ma L; Xiang BD; Li LQ
Clin Transl Oncol; 2017 Jul; 19(7):891-897. PubMed ID: 28160206
[TBL] [Abstract][Full Text] [Related]
4. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma.
Yau T; Tang VY; Yao TJ; Fan ST; Lo CM; Poon RT
Gastroenterology; 2014 Jun; 146(7):1691-700.e3. PubMed ID: 24583061
[TBL] [Abstract][Full Text] [Related]
5. Goals and targets for personalized therapy for HCC.
Couri T; Pillai A
Hepatol Int; 2019 Mar; 13(2):125-137. PubMed ID: 30600478
[TBL] [Abstract][Full Text] [Related]
6. An overview in management of hepatocellular carcinoma in Hong Kong using the Hong Kong Liver Cancer (HKLC) staging system.
Chui AMN; Yau TCC; Cheung TT
Glob Health Med; 2020 Oct; 2(5):312-318. PubMed ID: 33330826
[TBL] [Abstract][Full Text] [Related]
7. Multicentric Assessment of the Hong Kong Liver Cancer Staging System in Chinese Patients Following Transarterial Chemoembolization.
Zhong BY; Ni CF; Yin GW; Chen L; Zhu HD; Guo JH; He SC; Deng G; Zhang Q; Li PC; Yu H; Teng GJ
Cardiovasc Intervent Radiol; 2018 Dec; 41(12):1867-1876. PubMed ID: 30073478
[TBL] [Abstract][Full Text] [Related]
8. Hong Kong Liver Cancer Staging System Is Associated With Better Performance for Hepatocellular Carcinoma: Special Emphasis on Viral Etiology.
Liu PH; Hsu CY; Lee YH; Su CW; Hsia CY; Huang YH; Chiou YY; Lin HC; Huo TI
Medicine (Baltimore); 2015 Oct; 94(41):e1772. PubMed ID: 26469917
[TBL] [Abstract][Full Text] [Related]
9. Barcelona Clinic Liver Cancer outperforms Hong Kong Liver Cancer staging of hepatocellular carcinoma in multiethnic Asians: Real-world perspective.
Li JW; Goh BG; Chang PE; Tan CK
World J Gastroenterol; 2017 Jun; 23(22):4054-4063. PubMed ID: 28652658
[TBL] [Abstract][Full Text] [Related]
10. An evidence-based multidisciplinary approach to the management of hepatocellular carcinoma (HCC): the Alberta HCC algorithm.
Burak KW; Kneteman NM
Can J Gastroenterol; 2010 Nov; 24(11):643-50. PubMed ID: 21157578
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic advances for patients with intermediate hepatocellular carcinoma.
Sun JY; Yin T; Zhang XY; Lu XJ
J Cell Physiol; 2019 Aug; 234(8):12116-12121. PubMed ID: 30648254
[TBL] [Abstract][Full Text] [Related]
12. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system.
Han K; Kim JH
World J Gastroenterol; 2015 Sep; 21(36):10327-35. PubMed ID: 26420959
[TBL] [Abstract][Full Text] [Related]
13. Treatment strategies of intermediate-stage hepatocellular carcinomas in Japan (Barcelona Clinic Liver Cancer stage B).
Yamakado K; Kudo M
Oncology; 2014; 87 Suppl 1():78-81. PubMed ID: 25427737
[TBL] [Abstract][Full Text] [Related]
14. HKLC Triages More Hepatocellular Carcinoma Patients to Curative Therapies Compared to BCLC and Is Associated with Better Survival.
Wallace MC; Huang Y; Preen DB; Garas G; Adams LA; MacQuillan G; Tibballs J; Ferguson J; Samuelson S; Jeffrey GP
Dig Dis Sci; 2017 Aug; 62(8):2182-2192. PubMed ID: 28547649
[TBL] [Abstract][Full Text] [Related]
15. Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia.
Han KH; Kudo M; Ye SL; Choi JY; Poon RT; Seong J; Park JW; Ichida T; Chung JW; Chow P; Cheng AL
Oncology; 2011; 81 Suppl 1():158-64. PubMed ID: 22212951
[TBL] [Abstract][Full Text] [Related]
16. Effect of pre- and post-treatment α-fetoprotein levels and tumor size on survival of patients with hepatocellular carcinoma treated by resection, transarterial chemoembolization or radiofrequency ablation: a retrospective study.
Toro A; Ardiri A; Mannino M; Arcerito MC; Mannino G; Palermo F; Bertino G; Di Carlo I
BMC Surg; 2014 Jul; 14():40. PubMed ID: 24993566
[TBL] [Abstract][Full Text] [Related]
17. Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study.
Chen R; Gan Y; Ge N; Chen Y; Wang Y; Zhang B; Wang Y; Ye S; Ren Z
J Vasc Interv Radiol; 2016 Dec; 27(12):1829-1836. PubMed ID: 27553917
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in the treatment of hepatocellular carcinoma.
Padhya KT; Marrero JA; Singal AG
Curr Opin Gastroenterol; 2013 May; 29(3):285-92. PubMed ID: 23507917
[TBL] [Abstract][Full Text] [Related]
19. Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective.
Colombo M; Raoul JL; Lencioni R; Galle PR; Zucman-Rossi J; Bañares R; Seehofer D; Neuhaus P; Johnson P
Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):639-51. PubMed ID: 23628963
[TBL] [Abstract][Full Text] [Related]
20. A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016.
Yu SJ
Clin Mol Hepatol; 2016 Mar; 22(1):7-17. PubMed ID: 27044761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
